

AstraZeneca is pleased to announce the availability of a film-coated tablet formulation of CALQUENCE® (acalabrutinib).¹ CALQUENCE capsules will still be available for prescription and usage for a limited period of time.

CALQUENCE tablets have been proven to be bioequivalent to CALQUENCE capsules.² Other than the formulation, the notable difference between CALQUENCE tablets and capsules is that the tablets can be co-administered concomitantly in patients who require gastric acid-reducing agents (eg, proton pump inhibitors, H2-receptor antagonists, and antacids).^{1,3}

Please see the attached [flash card](#) for more information about the CALQUENCE reformulation.

PRODUCT AVAILABILITY

CALQUENCE is available through the following Specialty Distributors:

- AmerisourceBergen
- Cardinal Health Specialty Distribution
- CuraScript SD
- McKesson Specialty

Thank you for your ongoing support of AstraZeneca products and the patients they serve.

Indications and Usage

CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

CALQUENCE is also indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Select Safety Information

Serious adverse events, including fatal events, have occurred in patients with hematological malignancies treated with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation and flutter. The most common adverse reactions (≥20%) of any grade in patients with relapsed or refractory MCL were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising. The most common adverse reactions (≥30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.

Please see full [Prescribing Information](#), including [Patient Information](#).

You may report side effects related to AstraZeneca products by clicking [here](#).

References:

1. CALQUENCE® (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.

2. Sharma S, Pepin X, Burri H, et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). *Blood*. 2021;138(suppl_1):4365. doi:10.1182/blood-2021-146610

3. CALQUENCE® (acalabrutinib) capsules [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.

[4. Data on File, US-63024, AstraZeneca Pharmaceuticals LP; 2022.]

CALQUENCE is a registered trademark of the AstraZeneca group of companies.

©2022 AstraZeneca. All rights reserved. US-62918 Last Updated 8/22